Cempra, Inc. (CEMP) Cut to “Sell” at Zacks Investment Research

Cempra, Inc. (NASDAQ:CEMP) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued to investors on Tuesday.

According to Zacks, “Cempra Holdings, LLC is a pharmaceutical company engaged in developing antibiotics for the treatment of bacterial infectious diseases. It focuses on developing antibiotics for treating respiratory tract, skin and skin structure infections and to target the growing problem of antimicrobial resistance. Cempra Holdings, LLC is headquartered in Chapel Hill, North Carolina. “

A number of other equities analysts have also recently commented on CEMP. Stifel Nicolaus reiterated a “hold” rating and issued a $4.00 target price on shares of Cempra in a report on Thursday, August 10th. Roth Capital cut Cempra from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $8.00 to $4.00 in a report on Thursday, August 10th. Finally, Jefferies Group LLC reiterated a “hold” rating and issued a $3.00 target price on shares of Cempra in a report on Thursday, September 14th. Five analysts have rated the stock with a sell rating, eleven have assigned a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $10.00.

Shares of Cempra (NASDAQ CEMP) traded up 1.59% during mid-day trading on Tuesday, reaching $3.20. The company’s stock had a trading volume of 1,071,481 shares. The company has a 50-day moving average price of $3.09 and a 200 day moving average price of $3.73. Cempra has a 52-week low of $2.55 and a 52-week high of $24.48. The company’s market cap is $168.02 million.

Cempra (NASDAQ:CEMP) last announced its earnings results on Wednesday, August 9th. The biotechnology company reported ($0.23) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.32) by $0.09. The firm had revenue of $0.86 million during the quarter, compared to analysts’ expectations of $3.58 million. Cempra had a negative return on equity of 53.99% and a negative net margin of 560.40%. The company’s quarterly revenue was down 74.9% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.51) EPS. Equities analysts expect that Cempra will post ($1.01) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This piece was posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this piece on another site, it was stolen and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this piece can be read at https://ledgergazette.com/2017/10/10/cempra-inc-cemp-cut-to-sell-at-zacks-investment-research.html.

Hedge funds and other institutional investors have recently modified their holdings of the business. Janney Montgomery Scott LLC raised its position in Cempra by 35.6% during the 2nd quarter. Janney Montgomery Scott LLC now owns 25,900 shares of the biotechnology company’s stock valued at $119,000 after purchasing an additional 6,800 shares in the last quarter. Teachers Advisors LLC raised its position in Cempra by 5.2% during the 4th quarter. Teachers Advisors LLC now owns 93,481 shares of the biotechnology company’s stock valued at $262,000 after purchasing an additional 4,632 shares in the last quarter. Dynamic Technology Lab Private Ltd bought a new stake in Cempra during the 1st quarter valued at $187,000. Asset Management One Co. Ltd. bought a new stake in Cempra during the 1st quarter valued at $106,000. Finally, Morgan Stanley raised its position in Cempra by 47.0% during the 1st quarter. Morgan Stanley now owns 376,552 shares of the biotechnology company’s stock valued at $1,412,000 after purchasing an additional 120,372 shares in the last quarter. 49.75% of the stock is owned by institutional investors and hedge funds.

About Cempra

Cempra, Inc is a clinical-stage pharmaceutical company. The Company focuses on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases. Its product, solithromycin (CEM-101), which is a macrolide and fluoroketolide, is being developed in oral capsules, intravenous (IV) and suspension formulations for the treatment of community-acquired bacterial pneumonia (CABP).

Analyst Recommendations for Cempra (NASDAQ:CEMP)

Receive News & Ratings for Cempra Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cempra Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply